ClinicalTrials.gg
RecruitingNCT07376889COMBAT-SABUpdated Sep 25, 2026

Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

A Phase 4 interventional study of Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) and Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) in Staphylococcus Aureus Bacteremia, sponsored by Intermountain Health Care, Inc.. Recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Intermountain Health Care, Inc. · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Sep 25, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,096
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Bacteremia with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Bacteremia · United States.

Planned enrollment
3rd of 45
2,096 · median 85
Started
2026
with 2 others
Phase 4
11 of 79
2 open now
Registered
77th of 79
by date

Among the 79 studies in Bacteremia with a site in United States, this one is the 3rd largest by planned enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 in phase 4, and was the 77th registered.

Bacteremia

298 studies on the registry are indexed under Bacteremia; 50 are open to participants now.

Browse Bacteremia studies →

Open to participants now

6 of the 79 studies in Bacteremia with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Bacteremia studies recruiting now, 31 (79%) set no upper age limit and 4 (10%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Bacteremia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to see if, in selected patients with a serious bacterial infection of the bloodstream, treating the bacterial infection with a combination of antibiotics is more effective than treating the infection with a single antibiotic. Participants must have blood cultures which are positive for a certain type of bacteria.

Read the detailed description

Staphyloccocus aureus bacteremia (SAB) is a common infectious disease condition in hospitalized patients which is associated with significant morbidity, excessive costs, and high mortality, despite effective antibiotic therapy. This pragmatic study is designed to test the hypothesis that outcomes in adults hospitalized with SAB will be improved by using combination antibiotic therapy (CAT) as early, targeted therapy in a high-risk subgroup. A group of patients identified early in their course as meeting at least one high-risk criterion who have no contraindications will be treated with one of two antibiotic strategies commonly used within usual care, namely: 1) antibiotic monotherapy or 2) combination antibiotic therapy, depending on the random assignment for each hospital, each month. Low-risk patients will be treated per usual care. Data from all patients admitted to participating hospitals with SAB will be included in the analysis.

03

Conditions studied

  • Staphylococcus Aureus Bacteremia

Browse trials for

Keywords

  • Combination antibiotic therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Alive and admitted to an Intermountain Health (IH) hospital acute care unit at enrollment
  • Initial positive blood culture with either methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-susceptible Staphylococcus aureus (MSSA), collected:

    1. on or during the index admission to an IH hospital, or
    2. in an ambulatory setting (laboratory, clinic or emergency department) within 48 hours of the index admission, or
    3. at a non-IH network hospital within 24 hours of subsequent transfer to an IH hospital

Exclusion criteria

Exclusion Criteria:

  • Patient requests that patient health data not be included in the analysis
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
2,096 participants (estimated)

Study arms

  • Experimental
    Patients with methicillin-sensitive S. aureus bacteremia (MSSAB)

    Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) will be assigned to one of two different antibiotic treatment strategies appropriate for MSSA: 1) antibiotic monotherapy, or 2) combination antibiotic therapy

    Drug: Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB) · Drug: Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)

  • Experimental
    Patients with methicillin-resistant S. aureus bacteremia (MRSAB)

    Patients with methicillin-resistant S. aureus bacteremia (MRSAB) will be assigned to one of two different antibiotic treatment strategies appropriate for MRSA: 1) antibiotic monotherapy, or 2) combination antibiotic therapy

    Drug: Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB) · Drug: Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)

Interventions

  • DrugAntibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)

    Intravenous anti-staphylococcal beta-lactam, either cefazolin or nafcillin, per the discretion of the treating physician.

  • DrugAntibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)

    Vancomycin or daptomycin, per discretion of the treating physician

  • DrugCombination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB)

    Patients with methicillin-sensitive S. aureus bacteremia (MSSAB) and no contraindications will receive an anti-staphylococcal beta-lactam, either cefazolin or nafcillin, plus ertapenem

  • DrugCombination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)

    Daptomycin plus ceftaroline

06

What researchers measure

Primary outcomes

  1. Desirability of Outcome Ranking (DOOR)

    The DOOR ordinal scale includes four possible outcomes: treatment failure, infectious complications, antibiotic-associated adverse events and death. The ordinal scale comprises five levels: levels 1-4 are defined by survival at 30 days and the presence of either none, one, two or three of three possible outcomes; level 5 indicates death before 30 days. A DOOR analysis estimates the probability that overall outcomes in any given subject in one group are overall superior to those in a random subject from the other treatment group; probabilities \>50% reject the null hypothesis.

    Time frame: From enrollment to 30 days post enrollment

Secondary outcomes

  1. 90-day hospital-free days alive

    Number of days the patient is alive and out of the hospital

    Time frame: From enrollment to 90 days after enrollment

  2. 30-day all cause mortality

    Number of deaths from any cause within 30 days after enrollment

    Time frame: From enrollment to 30 days after enrollment

  3. 90-day all-cause mortality

    Number of deaths from any cause within 90 days after enrollment

    Time frame: From enrollment to 90 days after enrollment

  4. 30-day bacteremia-free days

    Number of days without bacteremia within 30 days after enrollment

    Time frame: From enrollment to 30 days after enrollment

  5. Length of stay

    Number of days in the hospital following enrollment

    Time frame: Measured at the time of hospital discharge, up to 30 days after enrollment

  6. Total hospital direct costs

    Total financial charges incurred by a patient during their hospitalization

    Time frame: Measured at the time of hospital discharge, up to 30 days after enrollment

  7. Total inpatient antibiotic cost

    Total cost of all antibiotics received by a patient while hospitalized

    Time frame: Measured at the time of hospital discharge, up to 30 days after enrollment

  8. Combination antibiotic days

    Number of days a patient receives combination antibiotic therapy (CAT) as defined in protocol, instead of antibiotic monotherapy (AM)

    Time frame: Measured from the time of enrollment until study day 7, death, or hospital discharge

  9. Antibiotic-associated adverse events

    Number and type of patient adverse events definitively associated with the receipt of antibiotics while hospitalized

    Time frame: From enrollment to 30 days after enrollment

  10. Clostridioides difficile infection

    Presence of infection with Clostridioides difficile while hospitalized

    Time frame: From enrollment to 30 days after hospital discharge

07

Study locations

13 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — In order to protect patient privacy and comply with relevant regulations, identified data will be unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org

Time frame: Data sharing will be available six months after anticipated enrollment completion, estimated August 2029, for a period to be determined by the Intermountain Office of Research and IRB

Access criteria: Will be determined on an individual basis, upon request to the IH Office of Research.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jan 2029, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 29, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites changed recruiting status (12 now recruiting)
Show 12 sites
  • Platte Valley Hospital · Brighton, United StatesNot yet recruiting→Recruiting
  • Saint Joseph Hospital · Denver, United StatesNot yet recruiting→Recruiting
  • St. Mary's Regional Hospital · Grand Junction, United StatesNot yet recruiting→Recruiting
  • Good Samaritan Hospital · Lafayette, United StatesNot yet recruiting→Recruiting
  • Lutheran Medical Center · Wheat Ridge, United StatesNot yet recruiting→Recruiting
  • St. Vincent Regional Hospital · Billings, United StatesNot yet recruiting→Recruiting
  • St. James Hospital · Butte, United StatesNot yet recruiting→Recruiting
  • Holy Rosary Hospital · Miles City, United StatesNot yet recruiting→Recruiting
  • McKay-Dee Hospital · Ogden, United StatesNot yet recruiting→Recruiting
  • Utah Valley Hospital · Provo, United StatesNot yet recruiting→Recruiting
  • LDS Hospital · Salt Lake City, United StatesNot yet recruiting→Recruiting
  • St. George Regional Hospital · St. George, United StatesNot yet recruiting→Recruiting
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    12 sites changed recruiting status (12 now recruiting)
    Show 12 sites
    • Platte Valley Hospital · Brighton, United StatesNot yet recruiting→Recruiting
    • Saint Joseph Hospital · Denver, United StatesNot yet recruiting→Recruiting
    • St. Mary's Regional Hospital · Grand Junction, United StatesNot yet recruiting→Recruiting
    • Good Samaritan Hospital · Lafayette, United StatesNot yet recruiting→Recruiting
    • Lutheran Medical Center · Wheat Ridge, United StatesNot yet recruiting→Recruiting
    • St. Vincent Regional Hospital · Billings, United StatesNot yet recruiting→Recruiting
    • St. James Hospital · Butte, United StatesNot yet recruiting→Recruiting
    • Holy Rosary Hospital · Miles City, United StatesNot yet recruiting→Recruiting
    • McKay-Dee Hospital · Ogden, United StatesNot yet recruiting→Recruiting
    • Utah Valley Hospital · Provo, United StatesNot yet recruiting→Recruiting
    • LDS Hospital · Salt Lake City, United StatesNot yet recruiting→Recruiting
    • St. George Regional Hospital · St. George, United StatesNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07376889
Responsible party
Brandon Webb (Associate Professor of Research, Division of Infectious Diseases, Intermountain Health Care, Inc.) — Principal investigator
First posted
Jan 29, 2026
Start date
Feb 1, 2026
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Sep 25, 2026

Study contacts

Brandon J Webb, MD
Contact
Brandon.Webb@imail.org
801-507-7781
Whitney R Buckel, PharmD
Contact
Whitney.Buckel@imail.org
801-284-1046
Brandon J Webb, MD
principal investigator · Intermountain Health Care, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion